share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144:拟议出售证券
美股SEC公告 ·  12/21 06:05

Moomoo AI 已提取核心信息

Arcutis Biotherapeutics, Inc. announced that Officer Todd Franklin Watanabe plans to sell 15,000 shares of common stock on 12/20/2024. The aggregate market value of the shares to be sold is $227,567.The shares to be sold were acquired through multiple Restricted Stock Vesting transactions between 02/27/2023 and 03/03/2024, totaling 15,000 shares from Arcutis Biotherapeutics Inc. This planned sale follows a recent transaction where Watanabe sold 13,871 shares on 11/04/2024 for gross proceeds of $120,039.The notice for this planned sale was dated 12/20/2024, with the plan adoption or instruction given on 06/14/2024. This transaction represents a continuation of the officer's stock selling activities, potentially for portfolio management or personal financial planning purposes.
Arcutis Biotherapeutics, Inc. announced that Officer Todd Franklin Watanabe plans to sell 15,000 shares of common stock on 12/20/2024. The aggregate market value of the shares to be sold is $227,567.The shares to be sold were acquired through multiple Restricted Stock Vesting transactions between 02/27/2023 and 03/03/2024, totaling 15,000 shares from Arcutis Biotherapeutics Inc. This planned sale follows a recent transaction where Watanabe sold 13,871 shares on 11/04/2024 for gross proceeds of $120,039.The notice for this planned sale was dated 12/20/2024, with the plan adoption or instruction given on 06/14/2024. This transaction represents a continuation of the officer's stock selling activities, potentially for portfolio management or personal financial planning purposes.
Arcutis生物治疗公司宣布,官员托德·富兰克林·渡边计划于2024年12月20日出售15,000股普通股。待售股票的总市场价值为227,567美元。待售股份是通过2023年2月27日到2024年3月3日期间的多次限制性股票归属交易获得的,总计15,000股来自Arcutis生物治疗公司。这次计划出售是在渡边于2024年11月4日出售13,871股,获得总收益120,039美元后的后续交易。这次计划出售的通知日期为2024年12月20日,计划的采用或指示是在2024年6月14日给出的。这项交易代表了该官员股票出售活动的延续,可能是出于投资组合管理或个人财务规划的目的。
Arcutis生物治疗公司宣布,官员托德·富兰克林·渡边计划于2024年12月20日出售15,000股普通股。待售股票的总市场价值为227,567美元。待售股份是通过2023年2月27日到2024年3月3日期间的多次限制性股票归属交易获得的,总计15,000股来自Arcutis生物治疗公司。这次计划出售是在渡边于2024年11月4日出售13,871股,获得总收益120,039美元后的后续交易。这次计划出售的通知日期为2024年12月20日,计划的采用或指示是在2024年6月14日给出的。这项交易代表了该官员股票出售活动的延续,可能是出于投资组合管理或个人财务规划的目的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息